Moving Deprescribing Beyond Potentially Harmful Medications
JAMA Network Open · 25.11.2024 · 7 (11) · e2446857
DOI: 10.1001/jamanetworkopen.2024.46857 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 25.11.2024. Verfasst von Julie C Lauffenburger. Beteiligte Einrichtung: Center for Healthcare Delivery Sciences, Brigham and Women's Hospital, Boston, Massachusetts. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Deprescribing, or the supervised process of intentionally reducing or stopping medication, has emerged as a strategy to reduce medication overuse and mitigate risks associated with taking multiple medications. 1 Odden and colleagues 2 evaluated the association of antihypertensive deprescribing with the risk of cardiovascular events, specifically myocardial infarction (MI) and stroke, among Veterans Health Administration long-term care residents. The investigators used an observational study design and electronic health record and administrative data with a target trial emulation framework approach, which helps estimate causal effects in situations like this one in which randomized clinical trials would be difficult. Based on data from 2006 to 2019 on 13096 adults aged 65 years or older, 18% of patients had medications deprescribed, defined as discontinuation or a 30% or greater reduction in dose; after up to 2 years of follow-up, the estimated cumulative incidence of hospitalization for MI or stroke was 11.2% in patients whose medications were deprescribed vs 8.8% in those whose medications were not (adjusted hazard ratio, 0.93; 95% CI, 0.70-1.26). Overall, the authors concluded that the adverse consequences of antihypertensive medication deprescribing, particularly major cardiovascular events, were likely to be minimal in this population. The rigorous study by Odden et al 2 challenges some conclusions of existing literature on deprescribing, which is relatively limited in terms of recency and clinical setting. 3 While low blood pressure targets less than 130/80 mm Hg (and even 120/80 mm Hg) are recommended for many patients under current guidelines, determining the right threshold for patients with complex health status, like those in long-term care settings, is less clear. The authors had access to electronic health record data to verify blood pressure values at the time of deprescribing, with median systolic and diastolic values of 127 mm Hg and 69 mm Hg, respectively, in the deprescribed group and 129 mm Hg and70mmHg,respectively,inthenotdeprescribedgroup;thesefindingssuggestthatdiscontinuing
Autor:innen und Institutionen
- Center for Healthcare Delivery Sciences, Brigham and Women's Hospital, Boston, Massachusetts.
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Zitieren
APA
Lauffenburger, J. C. (2024). Moving Deprescribing Beyond Potentially Harmful Medications. JAMA Network Open, 7(11), e2446857. https://doi.org/10.1001/jamanetworkopen.2024.46857
Vancouver
Lauffenburger JC. Moving Deprescribing Beyond Potentially Harmful Medications. JAMA Network Open. 2024;7(11):e2446857. doi:10.1001/jamanetworkopen.2024.46857
BibTeX
@article{Lauffenburger2024,
author = {Lauffenburger, Julie C},
title = {Moving Deprescribing Beyond Potentially Harmful Medications},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {11},
pages = {e2446857},
doi = {10.1001/jamanetworkopen.2024.46857}
}
EUVIMED